3 results
Approved WMOCompleted
The current study will focus on the effects of an intensive programme of exposure of prism adaptation (i.e. daily exposure during two weeks) and compare these to sham adaptation.
Approved WMOCompleted
To compare tumor [11C]erlotinib pharmacokinetics in NSCLC patients with and without erlotinib therapy. Also, to assess the relationship of venous sampling versus arterial, of tumor [11C]erlotinib uptake and blood flow with and without therapy, and…
Approved WMOCompleted
To evaluate interlesional and intralesional differences in [11C]erlotinib uptake in EGFR mutated (EGFR+) NSCLC patients who are at different stages in their TKI treatment. To correlate tumor [11C]erlotinib uptake to EGFR mutational status, tumor…